PDL BioPharma
Finance · Nevada, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
932 Southwood Blvd, Incline Village, Nev...Phone Number
(775) 832-8500Website
www.pdl.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
2
1
1
1
About PDL BioPharma
PDL BioPharma (NASDAQ: PDLI) manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired.Explore more
PDL BioPharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PDL BioPharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once PDL BioPharma has new funding data
Product Launch: Get notified when PDL BioPharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
PDL BioPharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if PDL BioPharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if PDL BioPharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at PDL BioPharma
Earning: See what the market has to say on PDL BioPharma recently announced quarterly report
Check out if PDL BioPharma is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to PDL BioPharma
Compare insights from companies similar to PDL BioPharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PDL BioPharma is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
PDL BioPharma is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about PDL BioPharma.
PDL BioPharma financials insights
Gather financial insights about PDL BioPharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$150M
PDL BioPharma Tech Stack
A closer look at the technologies used by PDL BioPharma
See more technologies
Most Recent Scoops
Earnings
PDL BioPharma has reported revenues of $6.00 million for the period ending on 3/31/2020.
Earnings
Management Move
Executive Move
Executive Moves
Earnings
PDL BioPharma has reported revenues of ($5.80) million for the period ending on 12/31/2019.
Earnings
Promotion
Executive Move
Executive Moves, Promotion
Executive Move
Executive Moves, Board of Directors
PDL BioPharma News & Media
PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat
RENO, Nev., Dec. 14, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments LLC ("Epps"). Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later...PDL Announces Timeline for Voluntarily Delisting from Nasdaq
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company's common stock from the Nasdaq Global Select Market ("Nasdaq"). PDL expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its common stock on or about December 28, 2020Recap: PDL BioPharma Q3 Earnings
Shares of PDL BioPharma (NASDAQ:PDLI) rose 7.96% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 211.11% year over year to ($0.10), which missed the estimate of $0.06. read more
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PDL BioPharma
Sign Up For FreeTo access detailed company insights
PDL BioPharma (NASDAQ: PDLI) manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired.... Read More
